The Mitochondrial Disease Sequence Data Resource (MSeqDR) is a central web portal that makes it easier to organize and analyze information from individuals and families with diagnosed and suspected mitochondrial disease. Currently, there is no mechanism in place to allow this group of individuals and families to choose who can access and analyze their information. The purpose of this project is to (1) Make it easier for participants to share their genomic data and (2) allow participants and/or their families to choose who can have access to and analyze these data, and how easily their data can be identified.

The purpose of this new clinical trial is to investigate study drug REN001 in adult patients with Primary Mitochondrial Myopathy. REN001 is currently not approved by the U.S. Food and Drug Administration nor any other regulatory agencies for this disease; it is considered an experimental drug. The study period will last for approximately 9 months and will include at least 4 outpatient visits at CHOP, where participants will be provided the study drug or placebo and monitored for safety. The study also involves blood and urine tests, cardiac tests, physical exercise tests, and other study procedures. For more information: https://www.clinicaltrials.gov/ct2/show/NCT04535609 Participants will be able to receive travel support and reimbursement for related expenses.